EGFR and colorectal carcinoma: Since the first targeted agent for CRC, the anti-EGFR agent cetuximab, was approved by the FDA in 2004, the antiangiogenic agent bevacizumab and the immune checkpoint inhibitor nivolumab have been launched successively42.